Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy

Official Title

Effects of Intracoronary Infusion of Bone Marrow-derived Progenitor Cells on Myocardial Regeneration in Patients With Non-ischemic Dilated Cardiomyopathy.

Brief Summary

      The main aim of the study is to determine whether intracoronary infusion of autologous bone
      marrow mononuclear cells can improve the ventricular function of patients with idiopathic
      dilated cardiomyopathy.Secondary end-points will be:

        1. To evaluate possible changes in patient functional capacity and

        2. to identify the biological characteristics of the bone marrow graft that might influence
           on functional recovery.

Detailed Description

      Clinical studies have shown that bone marrow cells can regenerate damaged myocardium after
      ischemic cardiopathy; however scarce information is available from patients with non-ischemic
      dilated cardiomyopathy. The aim of the present work is to investigate the role of
      intracoronary infusion of autologous marrow-derived stem cells in a phase II study in 30
      patients with dilated cardiomyopathy.Before the intracoronary transplant of marrow cells as
      well as six and twelve months thereafter, we will compare the ventricular function measured
      as left-ventricular ejection fraction by angiography, magnetic resonance imaging,
      echocardiography and treadmill direct oxygen consumption test. Functional capacity will be
      monitored throughout the study. In every condition of the study we will perform at least one
      30º right anterior oblique left ventricle (LV)angiogram. During each ventriculogram, attempts
      will be made to obtain a sinus and a post-extrasystolic beat for analysis, in order to study
      contractile reserve behaviours. Post-extrasystolic beats will be obtained by inducing
      premature beats with the catheter, once a well opacified cardiac cycle with a normal sinus
      beat had been filmed. In all instances, the r-r' interval of the induced premature beat and
      the post-extrasystolic pause will be recorded and measured.

      Measurements and calculations will be made off line in our own core lab, where end-diastolic
      and end-systolic silhouettes were drawn using the CASS system by 2 expert angiographers who
      were unaware of the patient group or study conditions. LV-volumes and ejection fraction (EF)
      were derived and regional wall motion was analyzed. The method by Sheehan (1) was used for
      the asynergy study, dividing the superimposed silhouettes in 100 radii of wall shortening,
      from end-diastole to end-systole. The abnormal contracting segment (ACS) was defined as the
      percentage of radii showing akinesia or dyskinesia. The areas of the ventrivular walls having
      asynergy will be regionally evaluated. The serial evolution of the contractile reserve will
      be evaluated by the post-extrasystolic potentiation.

      Coronary Flow Reserve (CFR) in all 3 coronary arteries will also be evaluated during every
      hemodynamic study (before treatment and 6 months after treatment). The FloMap® system
      (Cardiometrics; Mountain View; California) will be used. A 0.014" intracoronary Doppler guide
      wire will be positioned proximally in every coronary and flow velocities will be recorded
      continuously. Average peak velocity will be obtained at baseline and after an intracoronary
      bolus of Adenosine. CFR will be calculated as the ratio between maximal flow velocity during
      the peak effect of the adenosine injection and basal flow velocity.

      Magnetic Resonance Image (MRI) studies will be performed in 3 conditions (baseline, 3-month
      and 1-year after treatment). Functional parameters will be obtained in each condition,
      including LV-volumes, LV-mass and ejection fraction

      On the morning of cardiac catheterization, up to a volume of 100-150 ml of marrow will be
      obtained under local anesthesia by aspiration from the iliac crest. Mononuclear Bone Marrow
      Cells (MNBMCs) will be isolated by density gradient centrifugation over Ficoll-Hypaque
      technique in a sterile, semiautomated device COBE® 2991. After three washes, MNBMCs will be
      filtered and resuspended in 10 ml of 0.9% sodium chloride supplemented with preservative-free
      0.1% heparin. Aliquots will be obtained for cell count as well as for cytofluorometric and
      functional analyses of the cell content.

      Cells will be directly transferred to all 3 coronary arteries (50% to left anterior
      descending artery, 25% to the circumflex and 25% to the right coronary artery) by the use of
      a coaxial balloon catheter, which will be placed proximally at each artery. Balloon size will
      be selected according to vessel size, in order to achieve complete occlusion of the vessel
      and to stop flow during cell injection. So, backflow of cells is prevented and distal
      stagnant flow will facilitate cell exposure. The cell suspension will be injected through the
      distal tip of the balloon over 2 to 4 minutes.

      In addition,we will try to compare all possible changes in functional parameters with
      biological variables obtained from the marrow graft, such as:

        1. Number of cells positive for cluster of differentiation antigen (CD) CD146,CD31,
           CD133,CD90,CD38, CD117, CD73, CD105, CD45, Vascular endothelial growth factor receptor
           2,CXC-chemokine receptor 4 and HLA-DR.

        2. Functional characterization of endothelial progenitor cells and mesenchymal stem cells
           present in the graft by in vitro selective cultures.

        3. Analysis of the in vitro chemotactic ability of the infused cells.

        4. Determination of lineage-specific cardiac markers GATA-4 and Nk2.5/Csx in the infused
           marrow-derived cells. Correlations between these biological parameters and the effects
           on patient's ventricular function could highlight the role of each of the potential
           mechanisms implied in cell-mediated myocardial regeneration.

Study Phase

Phase 2

Study Type


Primary Outcome

Improvement of left ventricular function

Secondary Outcome

 Functional status


Dilated Cardiomyopathy


Intracoronary infusion of autologous bone marrow cells

Study Arms / Comparison Groups

Description:  All included patients are assigned to arm 1, in which they are treated by the intervention


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 2008

Completion Date

December 2010

Primary Completion Date

August 2010

Eligibility Criteria

        Inclusion Criteria:

          1. Patients of both genders with established clinical and angiographic diagnosis of
             Idiopathic Dilated Cardiomyopathy who accept to participate in the trial.

          2. They should have symptoms and/or signs of heart failure, despite optimized medical

          3. Angiographic ejection fraction should be less than 50%.

        Exclusion Criteria:

          1. Associated coronary artery disease.

          2. Any history or suspicion of a toxic, pharmacologic or deposit etiology.

          3. Absence of resynchronization therapy.

          4. Age longer than 80 years.

          5. Associated malignant or pre-malignant systemic disease.

          6. Associated hematologic disorder.




18 Years - 80 Years

Accepts Healthy Volunteers



Jose Suarez de Lezo, MD, PhD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Secondary IDs

EudraCT 2007-003088-36

Responsible Party


Study Sponsor

Fundación Pública Andaluza Progreso y Salud


 Iniciativa Andaluza en Terapias Avanzadas

Study Sponsor

Jose Suarez de Lezo, MD, PhD, Study Chair, Department of Cardiology. Reina Sofía University Hospital

Verification Date

May 2013